Skip to main content
Equibles
NAMS $21.80 +1.42%
NAMS logo
NAMS · NewAmsterdam Pharma Co N.V.
Track NAMS — free

Use NAMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NAMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.80 +0.31 (+1.42%)
Rebalance outlook locked
Market Cap
$2.57B
Shares
119.54M
Volume · Oct 22 798.59K Avg daily vol (3M) 1.39M
All webcasts

Earnings call · FY2026 Q2

NewAmsterdam Pharma Co N.V. (NAMS) Q2 2026 Earnings Call

Concluded Aug 5, 2026
Aug 5, 2026 0 turns
Period
FY2026 Q2
Runtime
—
Sources
3 artifacts
Revenue $3.70M -80.7% YoY
Diluted EPS -$0.52
Net income -$64.14M
Open full screen Slides 40 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 40 pages 8-K earnings release Filed Aug 5, 2026 10-Q report Filed Aug 5, 2026 Company webcastOpen the original investor-relations page
Full-screen source Call document

NAMS alerts

NewAmsterdam Pharma Co N.V.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →